CLAIMS

[Claim 1]

A transformation plasmid for an anaerobic bacterium, wherein the transformation plasmid is represented by the base sequence of pFGF110 (SEQ ID No: 14).

[Claim 2]

A transformation plasmid for an anaerobic bacterium, wherein the transformation plasmid is represented by the base sequence of pFGF111 (SEQ ID No: 15).

[Claim 3]

A gene transport carrier comprising an anaerobic bacterium transformed with the transformation plasmid according to Claim 1 or 2.

[Claim 4]

The gene transport carrier according to Claim 3, wherein the anaerobic bacterium is a *Bifidobacterium*.

[Claim 5]

The gene transport carrier according to Claim 4, wherein the *Bifidobacterium* is a *Bifidobacterium longum*.

[Claim 6]

A pharmaceutical composition comprising the gene transport carrier according to any one of Claims 3 to 5.

[Claim 7]

The pharmaceutical composition according to Claim 6, wherein the pharmaceutical composition further comprises an agent for promoting colonization and growth of the gene transport carrier at the site of an ischemic disease.

[Claim 8]

The pharmaceutical composition according to Claim 7, wherein the agent for promoting colonization and growth is at least one type selected from the group consisting of maltose, lactulose, arabinose, xylose, galactose, glucose, lactose, melibiose, melezitose, and raffinose.